Viking Therapeutics (VKTX) CFO sells 21,217 shares to cover taxes
Rhea-AI Filing Summary
Viking Therapeutics, Inc. CFO Greg Zante reported two stock transactions. On July 28, 2026 he acquired 31,667 shares of common stock at no cost when 33.33% of a performance restricted stock unit award granted January 3, 2023 vested after a non‑financial goal was met. On July 29, 2026, 21,217 shares were automatically sold on a non‑discretionary basis solely to satisfy tax withholding obligations, at a weighted‑average price of $33.4704 per share in multiple trades between $33.30 and $33.805.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 10,450 shares
Net Buy
2 txns
Insider
ZANTE GREG
Role
Chief Financial Officer
Sold
21,217 shs ($710K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, par value $0.00001 per share F3, F4 | 21,217 | $33.4704 | $710K |
| Grant/Award | Common Stock, par value $0.00001 per share F1, F2 | 31,667 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock, par value $0.00001 per share — 212,204 shares (Direct)
Footnotes (4)
- F1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
- F2. Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan
- F3. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Key Figures
RSU Shares Vested: 31,667 shares
Vested Portion of Award: 33.33%
RSU Grant Date: January 3, 2023
+5 more
8 metrics
RSU Shares Vested
31,667 shares
Common shares acquired at no cost on July 28, 2026 upon RSU vesting
Vested Portion of Award
33.33%
Portion of performance RSU award that vested July 28, 2026
RSU Grant Date
January 3, 2023
Grant date of the performance restricted stock unit award
Shares Sold for Taxes
21,217 shares
Common shares sold July 29, 2026 to satisfy tax withholding
Weighted‑Average Sale Price
$33.4704 per share
Average price for 21,217 shares sold July 29, 2026
Sale Price Range
$33.30–$33.805 per share
Price range for multiple sale transactions on July 29, 2026
2014 ESPP Shares
11,055 shares
Shares acquired May 20, 2024 under 2014 Employee Stock Purchase Plan
2024 ESPP Shares
808 shares
Shares acquired May 20, 2026 under 2024 Employee Stock Purchase Plan
Key Terms
performance restricted stock unit award, weighted average price, non-discretionary basis, tax withholding obligations, +1 more
5 terms
performance restricted stock unit award financial
"The reported securities were subject to a performance restricted stock unit award"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
non-discretionary basis financial
"These shares were automatically sold on a non-discretionary basis solely to satisfy"
tax withholding obligations financial
"sold on a non-discretionary basis solely to satisfy certain tax withholding obligations"
Employee Stock Purchase Plan financial
"shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Viking Therapeutics (VKTX) CFO Greg Zante report?
He reported a performance RSU vesting and a related tax sale. On July 28, 2026, 31,667 shares vested and were acquired at no cost. On July 29, 2026, 21,217 shares were automatically sold to cover tax withholding at a weighted‑average price of $33.4704.
What is the performance RSU award mentioned for Viking Therapeutics (VKTX)?
The report describes a performance restricted stock unit award granted on January 3, 2023. On July 28, 2026, 33.33% of this award vested after a non‑financial performance goal was achieved, resulting in the acquisition of 31,667 shares of Viking Therapeutics common stock.